Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2013-05-15
Adverse events
Moderate APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-30 (study day 16.0); relationship: PROBABLE
Moderate APPLICATION SITE DISCHARGE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-30 (study day 16.0); relationship: PROBABLE
Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-30 (study day 16.0); relationship: PROBABLE
Moderate COUGH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-09 (study day 26.0); relationship: NONE
Moderate DIARRHOEA — outcome: RECOVERED/RESOLVED; onset 2013-05-28 (study day 14.0); relationship: NONE
Moderate HIP FRACTURE — outcome: RECOVERED/RESOLVED; onset 2013-05-31 (study day 17.0); relationship: NONE
Mild SKIN LESION EXCISION — outcome: RECOVERED/RESOLVED; onset 2013-06-28 (study day 45.0); relationship: NONE
Moderate UPPER RESPIRATORY TRACT INFECTION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-09 (study day 26.0); relationship: NONE
Data queries
No data queries.